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ABSTRACT
Liver metastasis is the main cause of colon cancer-related death and is a 
recalcitrant disease. We report here the efficacy and safety of intra-portal-vein (iPV) 
targeting of Salmonella typhimurium A1-R on colon cancer liver metastasis in a nude-
mouse orthotopic model. Nude mice with HT29 human colon cancer cells, expressing 
red fluorescent protein (RFP) (HT29-RFP), growing in the liver were administered 
S. typhimurium A1-R by either iPV (1×104 colony forming units (CFU)/100 μl) or, 
for comparison, intra-venous injection (iv; 5×107 CFU/100 μl). Similar amounts of 
bacteria were delivered to the liver with the two doses, indicating that iPV delivery 
is 5×103 times more efficient than iv delivery. Treatment efficacy was evaluated by 
tumor fluorescent area (mm2) and total fluorescence intensity. Tumor fluorescent area 
and fluorescence intensity highly correlated (p<0.0001). iPV treatment was more 
effective compared to both untreated control and iv treatment (p<0.01 and p<0.05, 
respectively with iPV treatment with S. typhimurium arresting metastatic growth). 
There were no significant differences in body weight between all groups. The results 
of this study suggest that S. typhimurium A1-R administered iPV has potential for 
peri-operative adjuvant treatment of colon cancer liver metastasis.
INTRODUCTION
Liver metastasis is the main cause of colon-cancer-
related death [1]. In some cases, surgical resection of colon 
cancer liver metastasis is effective; however, the recurrence 
rate is extremely high [2]. The efficacy of adjuvant 
chemotherapy has been limited [3]. Therefore, development 
of effective treatment for colon cancer metastasis is needed.
The tumor-targeting Salmonella typhimurium A1-R 
(S. typhimurium A1-R), developed by our laboratory [4], is 
auxotrophic for Leu—Arg, which prevents it from mounting 
a continuous infection in normal tissues. S. typhimurium 
A1-R was effective against primary and metastatic tumors 
as monotherapy in nude mouse models of major cancers 
[5], including prostate [6, 7], breast [8–10], lung [11, 12], 
pancreatic [13–17], ovarian [18, 19] stomach [20], and 
cervical cancer [21], as well as sarcoma cell lines [22–25] 
and glioma [5, 26], all of which are highly aggressive tumor 
models. In addition, S. typhimurium A1-R was effective 
against patient-derived orthotopic models of pancreatic 
cancer [27, 28], sarcoma [25, 29–32] and melanoma [33].
In orthotopic mouse models, S. typhimurium A1-R, 
delivered iv, targeted liver metastases and significantly 
reduced their growth. The results of this previous 
study demonstrated the future clinical potential of S. 
typhimurium A1-R targeting of liver metastasis [34].
Regional chemotherapy of metastasis has resulted 
in higher levels of active 5-FU metabolites in the liver 
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[35, 36]. Previous studies have demonstrated that 5-FU 
administered directly into the portal vein adjuvantly 
may decrease distant metastases [37, 38]. Chang, et 
al. [39] reported that peri-operative intraportal (iPV) 
chemotherapy combined with adjuvant chemotherapy was 
useful to prolong disease-free survival after primary tumor 
resection and decreased liver metastasis for stage II and III 
colon-cancer patients without liver metastasis.
Previously, we administered 5-FU, ip, 2 h before 
hepatic resection of the human colon tumors, with therapy 
continued postoperatively for 4 consecutive days. We 
termed this procedure neo-neoadjuvant chemotherapy. 
Neo-neoadjuvant therapy significantly prolonged animal 
survival compared with standard preoperative 5-FU 
neoadjuvant therapy, 5-FU post-operative adjuvant therapy, 
surgery alone, 5-FU without surgery, or the untreated 
control. When all animals with neoadjuvant 5-FU 
treatment had died, 70% of animals with neo-neoadjuvant 
treatment were still alive. Survival of mice treated with 
5-FU without surgery, surgery alone, and adjuvant 
postoperative chemotherapy, was not significantly 
different from the untreated control group. Whereas 100% 
of animals in the control, 90% in the 5-FU alone, 70% in 
the surgery alone, 60% in the 5-FU adjuvant, and 40% 
in the neoadjuvant groups had metastases in the lymph 
nodes draining the liver, only 10% of animals in the neo-
neoadjuvant group had metastases [40].
The present study evaluates the efficacy and safety 
of iPV of S. typhimurium A1-R on colon cancer liver 
metastasis in a nude-mouse orthotopic model.
RESULTS AND DISCUSSION
iPV injection is more effective for delivery of 
S. typhimurium A1-R to the liver then iv injection
Two days after injection of S. typhimurium A1-R 
(iv: 5×107 CFU/100 μl; iPV: 1×104 CFU/100 μl) to mice 
without liver metastasis, the liver was removed and 
cultured on Luria-Bertani (LB) agar. The presence of S. 
typhimurium A1-R was confirmed by bright-field and 
GFP-expressing colony formation 24 hours after culture 
(Figure 1A-1D). There was no significant difference in 
colony formation between iv injection of 5×107 CFU/100 
μl and iPV injection of 1×104 CFU/100 μl S. typhiurium 
A1-R. These results showed that iPV injection was 5×103 
Figure 1: Culture of S. typhimurium A1-R from mouse liver. A-D. Representative images of S. typhimurium A1-R colony formation: 
Bright field (BF) (A) and fluorescence (FS) (B) after intravenous (iv) injection of S. typhimurium A1-R (5 x 107 CFU). BF (C) and FS (D) 
after intra-portal-vein (iPV) injection of S. typhimurim A1-R (1 x 104 CFU). The liver was minced and mixed with PBS and was seeded on 
LB-Agar with serial dilution in triplicate. Fluorescent S. typhimurium A1-R colonies were observed with the OV100 Small Animal Imaging 
System (Olympus Corp, Tokyo, Japan). E. S. typhimurium A1-R colony number in the liver after iv and iPV injection.
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times more effective for delivery of S. typhiurium A1-R to 
the liver than iv injection (Figure 1E).
Efficacy of S. typhimurium A1-R iPV injection on 
liver metastasis
The fluorescent area and total fluorescence intensity of 
HT29 growing in the liver were measured on day 14 (Figure 
2A) after iPV or iv injection of S. typhimurium A1-R. iPV 
delivery of S. typhiurium A1-R significantly suppressed 
growth of HT29 in the liver compared to both the untreated-
control group and iv treatment group (p<0.01, p<0.05, 
respectively) (Figure 2B, 2C), with IVP formatting arresting 
metastatic growth. There was no significant body-weight 
difference between the groups (Figure 3).
This is the first study to administer S. typhimurium 
A1-R via the iPV route to the liver directly. Most 
importantly, the treatment efficacy of iPV injection 
was significantly better than iv injection on HT29 cells 
growing in the liver.
Intra-operative therapy could be useful to decrease the 
risk of recurrence after cancer resection and could increase 
the surgical cure rate for colon-cancer liver metastasis 
patients. It has been reported that peri-operative intra-portal 
chemotherapy combined with adjuvant chemotherapy 
prolonged disease-free survival after primary tumor 
resection and decreased liver metastasis for stage II and III 
colon cancer patients, without liver metastasis [39].
These results are consistent with our previous 
studies which showed peri-operative “neo-neoadjuvant 
chemotherapy” was effective against colon-cancer liver 
metastasis in orthotopic nude mouse models [40].
In the present study, we demonstrated a strong 
correlation between tumor fluorescence area and 
fluorescence intensity (p<0.0001) (Figure 4). Fluorescence 
Figure 2: Efficacy of S. typhimurium A1-R on HT29-RFP liver metastasis. A. Pre-treatment and 14 days post-treatment of 
S. typhimurium A1-R: iv, 5 × 107 CFU/100μ; iPV, 1 × 104 CFU/100 μl. No treatment control (CTR). B-C. Bar graphs show the tumor 
fluorescent area (mm2) (B) and fluorescence intensity (C) at day 14. Scale bars: 5 mm.
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Figure 3: Safety evaluation of S. typhimurium A1-R therapy. Bar graph shows body weight in each group at pre-treatment and on 
day 14. There were no significant differences between the treated groups and control.
Figure 4: Correlation of tumor fluorescent area in tumor fluorescence intensity. Tumor area significantly correlated with 
fluorescence intensity (p<0.0001).
Oncotarget19069www.impactjournals.com/oncotarget
intensity of tumors could be a readily-measured simple 
parameter for determination of efficacy.
Intravital color-coded imaging of bacterial 
targeting of liver metastasis
Intravital color-coded imaging visualized S. 
typhimurium GFP targeting the HT29-RFP liver metastasis 
cells 14 days after iPV injection. The GFP-expressing 
bacteria can be seen growing in the HT29-RFP cells 
(Figure 5).
The present study develops a new concept of iPV 
delivery of tumor-targeting S. typhimurium A1-R to treat 
colon-cancer liver metastasis, the results of which are 
very promising. Bacterial therapy of cancer, which was 
first line for sarcoma and other cancers in the early part of 
the last century [5], is now having an exciting resurgence, 
including clinical trials [41].
Previously developed concepts and strategies of 
highly selective tumor targeting can take advantage of 
bacterial targeting of tumors [42–46].
Figure 5: Intravital imaging of S. typhimurium A1-R-GFP targeting HT29-RFP liver metastasis via iPV injection. S. 
typhimuriumu A1-R-GFP was visualized targeting the HT29-RFP liver metastases at day 14 after iPV injection. A. Liver metastases 
were visualized with the OV100 by fluorescence (left); brightfield (center) and merge (right). B. Confocal imaging with the FV1000 
demonstrated S. typhimuriumu A1-R-GFP targeting the HT29-RFP liver metastasis at the cellular level. Scale bars: (A) 5 mm; (B) Upper 
panels: 50 μm; Lower panels: 12.5 μm.
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MATERIALS AND METHODS
Cell line
HT29 human colon cancer cells expressing RFP 
[34, 47–49] were maintained in RPMI 1640 medium 
(Invitrogen, Carlsbad, CA, USA) supplemented with 
heat-inactivated 10% fetal bovine serum (FBS) (Gemini 
Biologic Products, Calabasas, CA), 2 mM glutamine, 100 
units/ml penicillin, 100 μg/ml streptomycin and 0.25 μg/
ml amphotericin B (Life Technologies, Inc., Grand Island, 
NY). The cells were incubated at 37°C in 5% CO2.
Mice
Athymic nu/nu nude mice (AntiCancer Inc., San 
Diego, CA), 4–6 weeks old, were used in this study. All 
mouse surgical procedures and imaging were performed 
with the animals anesthetized by subcutaneous injection 
of a ketamine mixture (0.02 ml solution of 20 mg/
kg ketamine, 15.2 mg/kg xylazine, and 0.48 mg/kg 
acepromazine maleate). All animal studies were conducted 
in accordance with the principles and procedures outlined 
in the National Institutes of Health Guide for the Care and 
Use of Animals under Assurance Number A3873-1.
Establishment of liver metastases
HT29-RFP cells were harvested by trypsinization 
and washed twice with serum-free medium. HT29-RFP 
cells (5×105 in 50 μl serum-free medium with 50% 
Matrigel) were injected into the superior and inferior pole 
of the spleen in nude mice. Three weeks after injection, 
experimental liver metastases were established.
Surgical orthotopic implantation of liver 
metastasis
Experimental liver metastases, as described above, 
were resected and cut into blocks (8 mm3). A single tumor 
block was orthotopically implanted into the left lobe of 
the liver in nude mice. Four weeks later, orthotopic liver 
metastasis were observed at the implanted site by RFP 
expression.
Preparation of S. typhimurium A1-R
GFP-expressing S. typhimurium A1-R bacteria 
(AntiCancer Inc.,) were grown overnight on LB medium 
(Fisher Sci., Hanover Park, IL, USA) and then diluted 1:10 
in LB medium. Bacteria were harvested at late-log phase, 
washed with PBS, and then diluted in PBS [6–8].
iPV injection
The anesthetized mice were placed in a supine 
position. After disinfecting the skin in the area of surgery, 
a median abdominal incision was performed followed by 
mobilization of the duodenum to identify the portal vein. 
S. typhimurium A1-R (100 μl) was injected into the portal 
vein using a 31 G needle. After removal of the needle, 
bleeding was stopped by gently pressing the puncture 
site with a cotton swab. After injection, the intestine was 
repositioned and the abdominal wall was closed with non-
absorbable sutures.
Targeting of the liver with S. typhimurium A1-R 
by iPV or iv routes
Nude mice without tumor were injected with S. 
typhimurium A1-R (iPV: 1×104 CFU; iv: 5×107 CFU). On 
day 2 after injection, the liver was resected, minced, and 
mixed with PBS. The minced liver was placed on LB agar 
to identify S. typhimurium A1-R. Fluorescent S. typhimurium 
A1-R bacteria were observed with the OV100 Small Animal 
Imaging System (Olympus Corp., Tokyo, Japan).
Imaging of tumor-targeted bacteria
The OV100 (Olympus) variable-magnification 
fluorescence imager [50] was used to image colonies of 
S. typhimurium A1-R from resected tumors. The FV1000 
confocal microscope (Olympus) [51] was used to image 
resected tumors for the presence of S. typhimurium A1-
R-GFP.
Efficacy of S. typhimurium A1-R on liver 
metastasis
Four weeks after orthotopic implantation of HT- 29-
RFP to the liver, 21 mice were randomized into 3 groups: 
untreated control group (n = 7); S. typhimurium A1-R iv 
treatment group (S. typhimurium A1-R, 5 × 107 CFU/body, 
iv, n = 7); and S. typhimurium A1-R iPV treatment group 
(S. typhimurium A1-R, 1 × 104 CFU/body, iPV, n = 7). The 
left lobe of the liver with metastasis was exposed before 
(at day 1) and after treatment (at day 15) for imaging 
with the OV100. The tumor fluorescent area and total 
fluorescence intensity were analyzed with UVP software 
(UVP, Upland, CA). Treatment efficacy in each mouse 
was evaluated by fluorescent area and total fluorescence 
intensity at day 15 compared to at the beginning of 
treatment. Liver metastasis in the S. typhimurium A1-R 
iPV treatment group was also imaged with the FV1000 
confocal microscope at day 15 to observe S. typhimurium 
A1-R-GFP targeting the RFP-expressing HT29 liver 
metastasis at the cellular level.
Statistical analysis
JMP version 11.0 was used for all statistical 
analyses. Significant differences for continuous variables 
were determined using the Mann-Whitney U test. Bar 
graphs expressed average values, and error bar showed 
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SE. A probability value of P ≤ 0.05 was considered 
statistically significant.
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